Details for Patent: 8,536,130

Which drugs does patent 8,536,130 protect, and when does it expire?

Patent 8,536,130 protects NUCYNTA ER and is included in one NDA.

This patent has eighteen patent family members in twelve countries.

Summary for Patent: 8,536,130

Title:	Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Abstract:	Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.
Inventor(s):	Christoph; Thomas (Aachen, DE), Friderichs; Elmar (Stolberg, DE), Koegel; Babette-Yvonne (Langerwehe-Hamich, DE), Meen; Murielle (Ayguesvives, FR)
Assignee:	Gruenenthal GmbH (Aachen, DE)
Application Number:	12/850,208
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,536,130
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,536,130

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No						MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No						MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-003	Aug 25, 2011		RX	Yes	No						MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011		RX	Yes	No						MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-005	Aug 25, 2011		RX	Yes	Yes						MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

Foreign Priority and PCT Information for Patent: 8,536,130

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2007 012 165	Mar 12, 2007

International Family Members for US Patent 8,536,130

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2680771
Cyprus	1115455
Germany	102007012165
Denmark	2117525
European Patent Office	2117525
Spain	2452830
Croatia	P20140280